Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6909202 | 0.76 | — | — | |
| SCHEMBL1191591 | 0.74 | — | — | |
| SCHEMBL7995031 | 0.74 | LMNA (0.35) | — | |
| SCHEMBL4456323 | 0.72 | — | — | |
| SCHEMBL2372061 | 0.69 | — | — | |
| SCHEMBL2840987 | 0.67 | LMNA (0.35) | — | |
| SCHEMBL8618134 | 0.67 | — | — | |
| SCHEMBL374490 | 0.65 | — | — | |
| SCHEMBL38852 | 0.65 | — | — | |
| SCHEMBL1932322 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312249-B2 | Vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-25 | — | — | US | claimed |
| US-20050182144-A1 | Novel vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-18 | — | — | US | claimed |
| EP-0664786-B1 | ARGININE KETO-AMIDE ENZYME INHIBITORS | CORVAS INT INC (US) | 1999-03-24 | — | — | EP | claimed |
| CN-117157295-A | Indoline-containing spiro derivative, preparation method and medical application thereof | 长春金赛药业有限责任公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-113354635-B | Pyrrolidine integrin regulator and application thereof | 清药同创(北京)药物研发中心有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115380054-A | Amine-modified polymers, controlled radical polymerization for their preparation and their implementation | 巴斯夫欧洲公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-110325565-B | Thermosetting resin composition | 旭化成株式会社 | 2022-03-22 | — | — | CN | disclosed |
| US-20210380577-A1 | PROCESS FOR MAKING HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210347962-A1 | COMPOSITIONS COMPRISING ESTOLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BIOSYNTHETIC TECHNOLOGIES, LLC (US) | 2021-11-11 | — | — | US | disclosed |
| EP-2727982-B1 | High- and low- viscosity estolide base oils and lubricants | BIOSYNTHETIC TECHNOLOGIES LLC (US) | 2021-11-10 | — | — | EP | disclosed |
| EP-3453748-B1 | ESTOLIDE BASE OILS AND OLIGOMERIC COMPOUNDS THAT INCLUDE CROSS METATHESIS | BIOSYNTHETIC TECHNOLOGIES LLC (US) | 2021-11-03 | — | — | EP | disclosed |
| US-5254565-A | Enzyme inhibitors; anticholesterol agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-19 | — | — | US | disclosed |
| EP-0558104-A1 | 1,5-Benzodiazepine derivatives and their use in medicine | GLAXO S.p.A. (IT) | 1993-09-01 | — | — | EP | disclosed |
| WO-1993014074-A1 | 1,5-BENZODIAZEPINE DERIVATIVES AND THEIR USE IN MEDICINE | GLAXO SPA (IT) | 1993-07-22 | — | — | WO | disclosed |
| WO-1993014075-A1 | CARBAMATE DERIVATIVES AND THEIR USE IN MEDICINE | GLAXO SPA (IT) | 1993-07-22 | — | — | WO | disclosed |
| US-5175180-A | Antagonist, antagonism | G. D. SEARLE & CO. (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0151282-B1 | OPTICALLY ACTIVE 3,4-BIS-(DIPHENYLPHOSPHINO)-PYRROLIDINE, RHODIUM COMPLEXES CONTAINING THEM AS CHIRAL LIGANDS, AND THEIR USE | Degussa Aktiengesellschaft (DE) | 1988-09-07 | — | — | EP | disclosed |
| EP-0151282-A1 | Optically active 3,4-bis-(diphenylphosphino)-pyrrolidine, rhodium complexes containing them as chiral ligands, and their use | Degussa Aktiengesellschaft (DE) | 1985-08-14 | — | — | EP | disclosed |
| EP-0088619-A2 | Benzopyrans | THE UPJOHN COMPANY (US) | 1983-09-14 | — | — | EP | disclosed |
| EP-0064027-A1 | Benzodioxole derivatives, process for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1982-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380577-A1 | PROCESS FOR MAKING HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, MAVS, HMBS | MEN1 4835/4885CYP3A4 65/4885ALOX15 3529/4885 |
| US-20050182144-A1 | Novel vitamin D analogues | CYP24A1, CYP2R1, VDR | MEN1 1405/4885CYP3A4 305/4885ALOX15 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.